Asterion Cannabis Inc. (“Asterion” or the “Company”), announces that, further to its news release dated April 24, 2019, the Company and its wholly-owned Australian subsidiary (“Asterion Australia”) have entered into an equity participation agreement dated June 18, 2019 (the “Equity Participation Agreement”) with Wellcamp Business Park Pty Ltd (“Wellcamp”), [an affiliate of Wagners Properties Pty Ltd] (“Wagners”).

Pursuant to the terms of the Equity Participation Agreement, Asterion and Asterion Australia have granted Wellcamp the option to settle a portion of certain invoices (each, an “Invoice”) rendered by Wellcamp to Asterion Australia for common shares in the capital of Asterion (each, an “Asterion Share”). The Invoices are anticipated to be rendered by Wellcamp in connection with goods and services to be provided to Asterion Australia in respect of the construction and development of Asterion’s Toowoomba Medicinal Cannabis Project (the “Toowoomba Project”), which was recently granted Major Project Status by the Federal Australian Government in early April 2019.


Stephen Van Deventer, the Company’s Chairman and CEO stated, “As Wagners and Wellcamp are expected to play an important role in the construction and development of the Toowoomba Project, we are pleased to be offering Wellcamp this equity participation option which is intended to provide Asterion with additional equity financing and offer Wellcamp the opportunity to share in the success of Asterion going-forward.”

Pursuant to the terms of the Equity Participation Agreement, Wellcamp, at its sole election, has been granted the option to take Asterion Shares as payment for up to 10% (and up to 100% with the prior approval of Asterion) of any Invoice that has been approved by Asterion. The Asterion Shares will have a deemed issuance price equal to the then current financing price of Asterion, or, if Asterion is not conducting a financing, at the last financing price. All Asterion Shares issued pursuant to the Equity Participation Arrangement will be subject to applicable stock exchange and regulatory approvals.

About the Toowoomba Project

The Toowoomba Project is located near the regional hub of Toowoomba, Queensland in close proximity to the Toowoomba Wellcamp Airport, which provides access to Queensland’s only dedicated 747-F international freighter service. The Toowoomba Project is planned to include a 40 hectare (4.3 million square feet) state-of-the-art greenhouse for cultivation and processing, in addition to a research centre and manufacturing facility, including administration and staff facilities. The Toowoomba Project is expected to be among the largest greenhouse facilities globally.

About Asterion

Asterion is a Canadian medicinal cannabis company with operations in Australia, specializing in medical cannabis and is focused on becoming an industry leader in next generation cannabis products. The Company is focused on the future of precision agriculture and aims to produce the highest quality genetically uniform cannabis strains, at an affordable price.

The Company is led by a team of highly experienced executives with over 120 years of combined experience in medical cannabis, renewable energy, capital markets, and other highly relevant sectors across North America, Oceania, Europe, Africa and Asia.

On Behalf of the Board of Directors

“Stephen Van Deventer”
Chairman & Chief Executive Officer

For further information, please contact:
Deanna Kress
+1-778-999-6063
info@asterioncannabis.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the construction and development of the Toowoomba Project, the Company’s and Asterion Australia’s ongoing business relationship with Wellcamp and Wagners, the Equity Participation Agreement and the exercise of the option granted to Wellcamp pursuant to same, the Company’s anticipated business plans, and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes”, “estimates” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward looking statements are based on certain assumptions regarding the Company and Asterion Australia, including that the Company and Asterion Australia will be able to obtain the financing and approvals needed to commence construction on and develop the Toowoomba Project and to carry out their planned future activities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, without limitation, the fact that the Equity Participation Agreement grants an option only and there is a no guarantee that such option will be exercised, and the inability of the Company and Asterion Australia to obtain the required approvals for the construction and operation of the Toowoomba Project, to execute its proposed business plans and to obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or cannabis industry, changes in general economic conditions, changes in the financial markets and in the demand and market price for cannabis, and delays in obtaining governmental and regulatory approvals, may also adversely affect the future results or performance of the Company and Asterion Australia. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

Click here to connect with Asterion Cannabis Inc. for an Investor Presentation.

Source: www.newsfilecorp.com

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less